Citi Pharma Limited (PSX:CPHL)
Pakistan · Delayed Price · Currency is PKR 61.66
-0.38 (-0.61%)
At close: Oct 16, 2026
Citi Pharma Income Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 14,076 | 13,154 | 12,409 | 12,397 | 9,780 | |
Revenue Growth | 7.01% | 6.00% | 0.10% | 26.76% | 68.75% |
Cost of Revenue | 11,603 | 11,136 | 10,823 | 10,890 | 8,417 |
Gross Profit | 2,473 | 2,018 | 1,586 | 1,507 | 1,363 |
Selling, General & Admin | 532.56 | 413.36 | 380.55 | 339.64 | 369.6 |
Operating Expenses | 532.56 | 413.36 | 380.55 | 339.64 | 369.6 |
Operating Income | 1,940 | 1,604 | 1,206 | 1,167 | 993.48 |
Interest Expense | -374.57 | -317.65 | -295.43 | -133.84 | -57.76 |
Interest & Investment Income | 91.65 | 181.89 | 23.77 | 13.54 | 20.95 |
Currency Exchange Gain (Loss) | -5.88 | -6.05 | 65.52 | -245.68 | -6.85 |
Other Non Operating Income (Expenses) | -307.36 | -121.52 | 256.3 | 175.03 | 110.75 |
EBT Excluding Unusual Items | 1,344 | 1,341 | 1,256 | 976.52 | 1,061 |
Gain (Loss) on Sale of Investments | 0.28 | 13.59 | 25.4 | -37.42 | - |
Other Unusual Items | - | - | - | 18.16 | - |
Pretax Income | 1,345 | 1,355 | 1,281 | 957.25 | 1,061 |
Income Tax Expense | 554.18 | 462.47 | 447.74 | 299.27 | 406.88 |
Net Income | 790.33 | 892.04 | 833.46 | 657.98 | 653.69 |
Net Income to Common | 790.33 | 892.04 | 833.46 | 657.98 | 653.69 |
Net Income Growth | -11.40% | 7.03% | 26.67% | 0.66% | 85.83% |
Shares Outstanding (Basic) | 228 | 228 | 228 | 228 | 227 |
Shares Outstanding (Diluted) | 228 | 228 | 228 | 228 | 227 |
Shares Change | - | - | - | 0.70% | 21.65% |
EPS (Basic) | 3.46 | 3.90 | 3.65 | 2.88 | 2.88 |
EPS (Diluted) | 3.46 | 3.90 | 3.65 | 2.88 | 2.88 |
EPS Growth | -11.40% | 7.03% | 26.67% | 0% | 53.04% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -544.63 | -470.77 | 769.4 | -1,283 | -923.43 |
Free Cash Flow Per Share | -2.38 | -2.06 | 3.37 | -5.62 | -4.07 |
Dividend Per Share | - | 3.500 | 3.250 | 2.500 | - |
Dividend Growth | - | 7.69% | 30.00% | 83.34% | - |
Gross Margin | 17.57% | 15.34% | 12.78% | 12.16% | 13.94% |
Operating Margin | 13.79% | 12.20% | 9.72% | 9.42% | 10.16% |
Profit Margin | 5.62% | 6.78% | 6.72% | 5.31% | 6.68% |
Free Cash Flow Margin | -3.87% | -3.58% | 6.20% | -10.35% | -9.44% |
EBITDA | 2,123 | 1,767 | 1,341 | 1,258 | 1,066 |
EBITDA Margin | 15.09% | 13.43% | 10.81% | 10.15% | 10.90% |
D&A For EBITDA | 183.06 | 162.75 | 135.67 | 90.59 | 72.84 |
EBIT | 1,940 | 1,604 | 1,206 | 1,167 | 993.48 |
EBIT Margin | 13.79% | 12.20% | 9.72% | 9.42% | 10.16% |
Effective Tax Rate | 41.22% | 34.14% | 34.95% | 31.26% | 38.36% |